Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.95 -0.50 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,622,346
Open 64.89
Bid (Size) 64.56 (3)
Ask (Size) 65.11 (16)
Prev. Close 65.45
Today's Range 64.61 - 65.36
52wk Range 57.16 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.37%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Palm Beach, FL – October 6, 2022 – FinancialNewsMedia.com News Commentary – The global Cervical Cancer Treatment market has been expanding for several years and is projected to continue at a growing... 
Via FinancialNewsMedia
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,500 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.67% on an annualized basis producing an average annual return of 14.39%. Currently, Gilead Sciences has a market... 
Via Benzinga

Performance

YTD
-10.51%
-10.51%
1 Month
+2.46%
+2.46%
3 Month
+3.54%
+3.54%
6 Month
+6.79%
+6.79%
1 Year
-3.64%
-3.64%

More News

Read More
A Bullish Sign Appears On Gilead Sciences's Chart
Via Benzinga
What Are Whales Doing With Gilead Sciences
Via Benzinga
Expert Ratings for Gilead Sciences
Via Benzinga
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
Via Benzinga
Why This Gilead Analyst Believes The Stock Is Highly Undervalued
Via Benzinga
Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio
Via Talk Markets
Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
From Gilead Sciences, Inc.
Via Business Wire
3 Biotech Stocks to Sell in October
Via InvestorPlace
Vietnam Law May Impact Facebook, Twitter; Amazon Has A Sleep Tracker; India Lures Apple, Dell, HP: Top Financial Media Stories Thursday, Sept. 29
Via Benzinga
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
Via Benzinga
7 Monthly Dividend Stocks to Buy for Safety
Via InvestorPlace
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market
Via InvestorPlace
Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Completes Acquisition of MiroBio
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $100 Invested In Gilead Sciences 15 Years Ago Would Be Worth Today
Via Benzinga
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Via Benzinga
NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly
Via Benzinga
7 Penny Stocks That Actually Have a Buy Rating
Via InvestorPlace
Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
From Gilead Sciences, Inc.
Via Business Wire
WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
From Gilead Sciences, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Delayed Generic Entry Is Positive For This Large Pharma's HIV Franchise Sales, Analyst Says
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.